A novel model of controlling PD-L1 expression in ALK
Journal
Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509
Informations de publication
Date de publication:
11 07 2019
11 07 2019
Historique:
received:
27
12
2018
accepted:
03
05
2019
pubmed:
4
6
2019
medline:
4
1
2020
entrez:
2
6
2019
Statut:
ppublish
Résumé
The success of programmed cell death protein 1 (PD-1)/PD-L1-based immunotherapy highlights the critical role played by PD-L1 in cancer progression and reveals an urgent need to develop new approaches to attenuate PD-L1 function by gaining insight into how its expression is controlled. Anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphoma (ALK
Identifiants
pubmed: 31151983
pii: S0006-4971(20)42422-X
doi: 10.1182/blood.2019001043
pmc: PMC6624970
doi:
Substances chimiques
B7-H1 Antigen
0
CD274 protein, human
0
ALK protein, human
EC 2.7.10.1
Anaplastic Lymphoma Kinase
EC 2.7.10.1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
171-185Subventions
Organisme : NCI NIH HHS
ID : K22 CA197014
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA006927
Pays : United States
Références
Oncogene. 1994 Jun;9(6):1567-74
pubmed: 8183550
Eur J Immunol. 2002 Mar;32(3):634-43
pubmed: 11857337
J Clin Oncol. 2016 Aug 10;34(23):2698-704
pubmed: 27269947
Nat Rev Cancer. 2017 May;17(5):286-301
pubmed: 28338065
Oncogene. 2017 Jul 13;36(28):4037-4046
pubmed: 28288138
Cancer Res. 2007 May 1;67(9):4278-86
pubmed: 17483340
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Leukemia. 2017 Jul;31(7):1633-1637
pubmed: 28344319
Oncotarget. 2017 Jun 27;8(26):42414-42427
pubmed: 28465490
Cancer Res. 2014 Feb 1;74(3):665-74
pubmed: 24336068
Sci Transl Med. 2016 Mar 2;8(328):328rv4
pubmed: 26936508
Clin Cancer Res. 2012 Mar 15;18(6):1611-8
pubmed: 22271878
Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20852-7
pubmed: 19088198
Nature. 2012 Oct 25;490(7421):502-7
pubmed: 22992524
Cancer Cell. 2018 Aug 13;34(2):286-297.e10
pubmed: 30057145
Science. 2014 Jan 3;343(6166):84-87
pubmed: 24336571
J Dent Res. 2017 Aug;96(9):1027-1034
pubmed: 28605599
Cancer Cell. 2012 Jun 12;21(6):723-37
pubmed: 22698399
Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7
pubmed: 12218188
Blood. 2010 Oct 28;116(17):3268-77
pubmed: 20628145
Blood. 2000 Mar 15;95(6):2084-92
pubmed: 10706878
Oncogene. 1997 May 8;14(18):2175-88
pubmed: 9174053
Nature. 2014 Nov 27;515(7528):563-7
pubmed: 25428504
Cancers (Basel). 2018 Jan 18;10(1):
pubmed: 29346274
Pigment Cell Melanoma Res. 2018 Jan;31(1):51-63
pubmed: 28755520
Science. 2016 Apr 8;352(6282):227-31
pubmed: 26966191
Eur Urol. 2016 Oct;70(4):623-632
pubmed: 26707870
Mol Cancer Res. 2012 Oct;10(10):1265-70
pubmed: 22871571
Nat Rev Cancer. 2008 Jan;8(1):11-23
pubmed: 18097461
Nature. 2011 Feb 3;470(7332):115-9
pubmed: 21179087
Science. 2012 Nov 16;338(6109):975-80
pubmed: 22983707
Leukemia. 2009 Mar;23(3):574-80
pubmed: 18987657
PLoS One. 2013 Apr 09;8(4):e61602
pubmed: 23585913
J Immunol. 2013 Dec 15;191(12):6200-7
pubmed: 24218456
Blood. 2015 Jan 1;125(1):124-32
pubmed: 25359993
Blood. 2015 May 14;125(20):3118-27
pubmed: 25833963
Nature. 2006 May 4;441(7089):106-10
pubmed: 16572121
Nat Rev Drug Discov. 2015 Aug;14(8):561-84
pubmed: 26228759
Science. 2014 Jan 3;343(6166):80-4
pubmed: 24336569
Nature. 2012 Oct 25;490(7421):543-6
pubmed: 22992523
Science. 1994 Mar 4;263(5151):1281-4
pubmed: 8122112
J Clin Oncol. 2016 Aug 10;34(23):2690-7
pubmed: 27069084
Cancer Sci. 2009 Nov;100(11):2093-100
pubmed: 19703193
N Engl J Med. 2016 Nov 3;375(18):1767-1778
pubmed: 27806234
Science. 2015 Apr 3;348(6230):56-61
pubmed: 25838373
J Biol Chem. 2010 Aug 20;285(34):26441-50
pubmed: 20554525
Leukemia. 2000 Mar;14(3):449-56
pubmed: 10720141